Drug Profile

Research programme: Smad3 inhibitors - Moexa Pharmaceuticals

Latest Information Update: 30 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Moexa Pharmaceuticals
Class Antifibrotics; Antineoplastics; Small molecules
Mechanism of Action Smad3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer; Fibrosis

Most Recent Events

21 Apr 2026 Receptor.AI and Moexa Pharmaceuticals agree to co-develop Smad3 inhibitors for Cancer and Fibrosis
21 Apr 2026 Moexa Pharmaceuticals has patent protection for Smad3 inhibitors in worldwide (Moexa Pharmaceuticals website, April 2026)
10 Feb 2025 Preclinical trials in Cancer in USA (unspecified route), prior to February 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com